

1204

+3012584620

T-923 P.01

Job-241

J. Timothy Meigs
Sector Patent Counsel

Genetic Therapy, Inc.
9 West Watkins Mill Road
Gaithersburg, MD 20878

Tel (301) 258-4715
Fax (301) 258-4620
Email: tim.meigs@pharma.novartis.com

#399

11/27/02

(NE)



GENETIC THERAPY, INC.
A Novartis Company

Fax

FAX RECEIVED

NOV 27 2002

GROUP 1600

Attention Examiner Ram R. Shukla, PTO Art Unit 1632

Fax no. (703) 308-4242

Number of
pages 7

Date Nov. 26, 2002

CONFIDENTIAL

RE: 08/704,445

Dear Examiner Shukla,

Please enter the attached amendment in application no. 08/704,445.

Respectfully submitted,

J. Timothy Meigs
Attorney for Applicant
Reg. No. 38,241

PRIVILEGED AND CONFIDENTIAL information intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and return the original to us at the address above via the U.S. Mail. Thank you.

NOVARTIS

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the
Patent Office Fax No. (703) 308-4242 on the date shown below.

J. Timothy Meigs J. Timothy Meigs 11/26/02
Type or Print Name Signature Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Chen et al.

Art Unit: 1632

Serial No. 08/704,445

Examiner: Shukla, Ram R.

Filed: August 26, 1996

Atty Docket: 4-127-1000P1/CONT/SYS

For: **Methods For Preventing Depletion
Of Non-Autologous Hematopoietic
Cells and Animal Model Systems
for Use Thereof**

Confirmation No. 9201

AMENDMENT AND RESPONSE

Commissioner for Patents
Washington, D.C. 20231

Sir:

Responsive to the Office Action of August 27, 2002 (Paper No. 38), Applicant respectfully requests reconsideration of the above-identified application in view of the following amendments and remarks.

It is believed that no extensions of time are necessary. However, if one is deemed necessary to maintain pendency of this application, the Commissioner is authorized to charge any fees under 37 C.F.R. §1.17 that may be required, or credit any overpayment, to Applicant's deposit account no. 19-0134.